Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Theriva Biologics Inc TOVX

Healthcare Biotechnology

Theriva Biologics, Inc. is a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. It is advancing a new oncolytic adenovirus platform. Its candidates are VCN-01, SYN-004 (ribaxamase) and SYN-020. VCN-01 is an oncolytic adenovirus designed to replicate selectively and aggressively within tumor cells, and to degrade... see more

Add To Watchlist

Recent & Breaking News (NYSEAM:TOVX)

Synthetic Biologics Reports Second Quarter 2021 Operational Highlights and Financial Results; Conference Call to be Held Today at 4:30 PM ET

PR Newswire August 5, 2021

Synthetic Biologics Expands Option for an Exclusive License Agreement with Massachusetts General Hospital

PR Newswire August 3, 2021

Synthetic Biologics to Report 2021 Second Quarter Operational Highlights and Financial Results on August 5, 2021

PR Newswire July 28, 2021

Synthetic Biologics Provides Update on SYN-020 Intestinal Alkaline Phosphatase Phase 1 Single-Ascending Dose Clinical Trial

PR Newswire June 29, 2021

Synthetic Biologics Regains Compliance with NYSE American Continued Listing Standards

PR Newswire May 26, 2021

Synthetic Biologics Reports 2021 First Quarter Operational Highlights and Financial Results

PR Newswire May 5, 2021

Synthetic Biologics to Report 2021 First Quarter Operational Highlights and Financial Results on May 5, 2021

PR Newswire April 28, 2021

Synthetic Biologics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients

PR Newswire April 14, 2021

Synthetic Biologics Announces First Six Participants Dosed in Phase 1a Clinical Trial of SYN-020 Intestinal Alkaline Phosphatase

PR Newswire April 1, 2021

Synthetic Biologics Reports 2020 Year End Operational Highlights and Financial Results

PR Newswire March 4, 2021

Synthetic Biologics to Report 2020 Year End Operational Highlights and Financial Results on March 4, 2021

PR Newswire February 25, 2021

Synthetic Biologics Announces Washington University School of Medicine in St. Louis IRB Approval of the SYN-004 (ribaxamase) Phase 1b/2a Clinical Protocol

PR Newswire December 22, 2020

Synthetic Biologics Announces Extension of Compliance Plan Period by NYSE American

PR Newswire November 24, 2020

Synthetic Biologics Engages A.G.P./Alliance Global Partners as Advisor to Assist in Evaluating Strategic Options

PR Newswire November 16, 2020

Synthetic Biologics Welcomes Senior Biotech Executive John Monahan, PhD, to Board of Directors

PR Newswire November 12, 2020

Synthetic Biologics Reports 2020 Third Quarter Operational Highlights and Financial Results

PR Newswire November 10, 2020

Synthetic Biologics to Report 2020 Third Quarter Operational Highlights and Financial Results on November 10, 2020

PR Newswire November 3, 2020

Synthetic Biologics Provides Update on Investigator-Sponsored Phase 2b Clinical Study of SYN-010 in IBS-C Patients

PR Newswire October 2, 2020

Synthetic Biologics Reports 2020 Second Quarter Operational Highlights and Financial Results

PR Newswire August 6, 2020

Synthetic Biologics Announces FDA Clearance of Investigational New Drug Application for SYN-020 Intestinal Alkaline Phosphatase (IAP)

PR Newswire July 30, 2020